China Biologic Products to Report Fourth Quarter and Fiscal Year 2012 Financial Results

    China Biologic Products to Report Fourth Quarter and Fiscal Year 2012
                              Financial Results

PR Newswire

BEIJING, March 8, 2013

BEIJING, March 8, 2013 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ:
CBPO, "China Biologic" or the "Company"), a leading fully integrated
plasma-based biopharmaceutical company in China, today announced that the
Company plans to release fourth quarter and fiscal year 2012 financial results
on Wednesday, March 13, 2013 after the market closes.

The Company's management will hold a conference call at 8:00 a.m. ET on
Thursday, March 14, 2013 to discuss fourth quarter and fiscal year 2012
results. Listeners may access the call by dialing:

U.S. toll free:                      +1 866 978 9970
U.K. toll free:                      +0 800 279 7785
Mainland China toll free (landline): 800 803 6103
Mainland China toll free (mobile):   400 681 6405
Hong Kong toll free:                 3027 5500
International toll:                  +852 3027 5500
Conference ID:                       674 477#

A telephone replay will become available beginning two hours after the
conclusion of the call and will remain available through March 20, 2013.
Listeners may access the replay by dialing:

U.S. toll free:     +1 866 753 0743
U.K. toll free:     +0 808 234 7126
Mainland China:     800 876 5016
Hong Kong:          3027 5520
International toll: +852 3027 5520
Conference ID:      138 012#

About China Biologic Products, Inc.

China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated
plasma-based biopharmaceutical company in China. The Company's products are
used as critical therapies during medical emergencies and for the prevention
and treatment of life-threatening diseases and immune-deficiency related
diseases. China Biologic is headquartered in Beijing and manufactures over 20
plasma-based products through its indirect majority-owned subsidiaries,
Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic
Technologies Co., Ltd. The Company also has an equity investment in Xi'an
Huitian Blood Products Co., Ltd. The Company sells its products to hospitals
and other healthcare facilities in China. For additional information, please
see the Company's website www.chinabiologic.com.

Contact:

China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: william.zima@icrinc.com

SOURCE China Biologic Products, Inc.

Website: http://www.chinabiologic.com
 
Press spacebar to pause and continue. Press esc to stop.